Literature DB >> 33435164

Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.

Arrigo F G Cicero1, Federica Fogacci1, Masanari Kuwabara2, Claudio Borghi1.   

Abstract

This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that further well-designed clinical research is needed to deepen their efficacy and safety profile.

Entities:  

Keywords:  hyperuricemia; uric acid; uric acid-lowering drugs; uricosurics; xanthine oxidase inhibitors

Mesh：

Substances：

Year:  2021        PMID： 33435164      PMCID： PMC7827966          DOI： 10.3390/medicina57010058

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN： 1010-660X            Impact factor:   2.430


  117 in total

1.  Febuxostat.

Authors:  Eliseo Pascual; Francisca Sivera; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

Review 2.  Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Authors:  Sebastian E Sattui; Angelo L Gaffo
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-05-02       Impact factor: 5.346

3.  The management of hyperuricemia: back to the pathophysiology of uric acid.

Authors:  Claudio Borghi
Journal:  Curr Med Res Opin       Date:  2017-11       Impact factor: 2.580

4.  Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.

Authors:  Mehmet G Kaya; Huseyin Uyarel; Mahmut Akpek; Nihat Kalay; Mehmet Ergelen; Erkan Ayhan; Turgay Isik; Gokhan Cicek; Deniz Elcik; Omer Sahin; Said M Cosgun; Abdurrahman Oguzhan; Mehmet Eren; C Michael Gibson
Journal:  Am J Cardiol       Date:  2011-11-17       Impact factor: 2.778

5.  Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.

Authors:  C H Pui
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

6.  Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.

Authors:  Umair Z Malik; Nicholas J Hundley; Guillermo Romero; Rafael Radi; Bruce A Freeman; Margaret M Tarpey; Eric E Kelley
Journal:  Free Radic Biol Med       Date:  2011-04-15       Impact factor: 7.376

7.  Loss of urate oxidase activity in hominoids and its evolutionary implications.

Authors:  Masako Oda; Yoko Satta; Osamu Takenaka; Naoyuki Takahata
Journal:  Mol Biol Evol       Date:  2002-05       Impact factor: 16.240

Review 8.  Gout: state of the art after a decade of developments.

Authors:  Tristan Pascart; Frédéric Lioté
Journal:  Rheumatology (Oxford)       Date:  2019-01-01       Impact factor: 7.580

9.  A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.

Authors:  Jeffrey Poiley; Alexandra S Steinberg; Yun-Jung Choi; Charles S Davis; Robert L Martin; Charles A McWherter; Pol F Boudes
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

10.  Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Authors:  Herbert S B Baraf; Michael A Becker; Sergio R Gutierrez-Urena; Edward L Treadwell; Janitzia Vazquez-Mellado; Claudia D Rehrig; Faith D Ottery; John S Sundy; Robert A Yood
Journal:  Arthritis Res Ther       Date:  2013-09-26       Impact factor: 5.156
View more
  10 in total

1.  Katsuwonus pelamis Peptide and its Complexes Protect Zebrafish and Mice From Hyperuricemia Through Promoting Kidney Excretion of Uric Acid and Inhibiting Liver Xanthine Oxidase Activity.

Authors:  Wei Wei; Li-Jian Zhou; Shue Wang; Zheng Zhang; Jia-Ying Huang; Zhao Zhang; Xi-Ping Zhang; Xue-Jun Zhang; Jie Li; Ye-Wang Zhang
Journal:  Front Chem       Date:  2022-06-28       Impact factor: 5.545

2.  Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.

Authors:  Jackelyn Murray; Harrison C Bergeron; Les P Jones; Zachary Beau Reener; David E Martin; Fred D Sancilio; Ralph A Tripp
Journal:  Viruses       Date:  2022-04-27       Impact factor: 5.818

Review 3.  Uric Acid and Hypertension: Prognostic Role and Guide for Treatment.

Authors:  Federica Piani; Arrigo F G Cicero; Claudio Borghi
Journal:  J Clin Med       Date:  2021-01-24       Impact factor: 4.241

4.  Combination of Uric Acid and Pro-Inflammatory Cytokines in Discriminating Patients with Gout from Healthy Controls.

Authors:  Xuwen Zha; Bo Yang; Guangyun Xia; Shan Wang
Journal:  J Inflamm Res       Date:  2022-02-28

5.  Tongbixiao Pills Improve Gout by Reducing Uric Acid Levels and Inhibiting Inflammation.

Authors:  Shijun Xi; Lu Li; Zhuang Gui; Peng Liu; Qi Jiang; Yuan Yu; Wen Zhou; Ziqi Zhou; Shuo Zhang; Xiao Chun Peng; Bo Su
Journal:  Dose Response       Date:  2022-04-09       Impact factor: 2.658

6.  Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study.

Authors:  Tatsuya Maruhashi; Yukihito Higashi; Hisako Yoshida; Atsushi Tanaka; Kazuo Eguchi; Hirofumi Tomiyama; Kazuomi Kario; Toru Kato; Nozomu Oda; Nobuhiro Tahara; Mitsutoshi Oguri; Hirotaka Watada; Koichi Node
Journal:  Front Cardiovasc Med       Date:  2022-04-28

Review 7.  Review of Urate-Lowering Therapeutics: From the Past to the Future.

Authors:  Christopher Jenkins; Jennifer H Hwang; Jeffrey B Kopp; Cheryl A Winkler; Sung Kweon Cho
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

8.  Potential role of tea drinking in preventing hyperuricaemia in rats: biochemical and molecular evidence.

Authors:  Siyao Sang; Lufei Wang; Taotao Liang; Mingjie Su; Hui Li
Journal:  Chin Med       Date:  2022-09-15       Impact factor: 4.546

9.  Xanthine oxidase inhibitory study of eight structurally diverse phenolic compounds.

Authors:  Arshad Mehmood; Jiayi Li; Ashfaq Ur Rehman; Rovina Kobun; Inam U Llah; Imran Khan; Fayez Althobaiti; Sarah Albogami; Muhammad Usman; Fahad Alharthi; Mohamed Mohamed Soliman; Sanabil Yaqoob; Kanza Aziz Awan; Liang Zhao; Lei Zhao
Journal:  Front Nutr       Date:  2022-09-20

10.  Long-Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study.

Authors:  Arrigo F G Cicero; Federica Fogacci; Elisabetta Rizzoli; Sergio D'Addato; Claudio Borghi
Journal:  J Clin Med       Date:  2021-12-17       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.